ARR in line with ABGSCe, adj. EBITDA weaker ~27% ARR growth in Q1 despite negative FX impact Reitera...
Redeye provides its initial take on Surgical Science’s Q1 2023 report, which exceeded our estimates ...
Redeye’s short comment on the announced management change.
Redeye concludes that Q1 came in softer than Redeye had estimated.
Redeye retains its positive view on Lagercrantz following a Q4 report with 9% organic growth and hea...
Redeye comments on Flexion Mobiles Q1 2023 report. A weaker report than expected.
Redeye comments on Thunderful Group’s Q1'23 report, which delivered stronger sales and profitability...
Twiik, utvecklaren av en digital träningsplattform, redovisade en nettoomsättning om 3,6 (2,9) miljo...
Callidita’s sequential Q1 growth accelerates in terms of unique subscribers and patient enrollment t...
Redeye comments on EG7’s Q1-results which was stronger than expected with revenue coming in 8% above...
Redeye comments on Embracer Groups preliminary figures for Adj EBIT of CSEK900m in Q4 2022/2023e.
Redeye comments on Klaria Pharma’s Q1 2023 report. The company reports continued validation of its e...
Redeye comments on Cantargia's new strategy to study nadunolimab in a controlled phase IIb study in ...
Redeye initiates coverage on Physitrack, a scalable and rapidly growing e-health software company th...
Redeye comments on Embracers Groups' agreement with Amazon Games to develop and publish a new game b...
SDS publicerade den 15 maj 2023 bolagets delårsrapport för det första kvartalet år 2023 och visar på...
Arctic Blue Beverages publicerade den 15 maj 2023 bolagets delårsrapport för det första kvartalet 20...
Med delårsrapporten för första kvartalet 2023 presenterad står det klart att TCECUR både försäljning...
IRLAB Therapeutics has reported Q123 results, providing a financial update and highlighting its near...
Tangiamo har inlett året 2023 starkt och uppvisade rekordintäkter om 7,4 MSEK under Q1-23, och dessu...
